Tradestie Institutional Equity Comparison Engine

BOLD vs ABIG โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BOLD Overall Edge

BOLD Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, BOLD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ABIG at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABIG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BOLD N/M vs ABIG N/M Fwd P/E
Growth & Margin Winner BOLD
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner BOLD
1Y +101.7% vs +1.3% ยท 52W Pos 62% vs 41%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
ABIG NASDAQ
Argent Large Cap ETF
Institutional Equity
$31.73
-3.67% 1D
Market Cap N/A
1M Return -9.65%
1Y Return +1.31%
Forward P/E N/M
Unified AI Score
46.8 / 100 HOLD
Tech 36.0 Fund 48.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BOLD +101.74% ABIG +1.31% Spread: +100.15 pp (BOLD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BOLD TTM Op. Margin: 0.0% ABIG TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs ABIG. Trailing 12-month operating profitability (BOLD 0.0% vs ABIG N/A) and valuation multiples (BOLD N/M vs ABIG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BOLD (6) vs ABIG (2)
Institutional Metric BOLD ABIG Criterion Row Winner
Market Capitalization Scale $56.2M N/A Larger Scale BOLD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth BOLD
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin BOLD
Net Profit Margin Profitability 0.0% N/A Higher Margin BOLD
Return on Equity (ROE) Capital Efficiency -64.6% N/A Higher ROE BOLD
52-Week Range Position Momentum 62% ($1โ€“$3) 41% ($28โ€“$36) Stronger Trend BOLD
Beta / 30D Volatility Risk Regime -0.08ฮฒ ยท 28% Vol 1.00ฮฒ ยท 22% Vol Lower Realized Risk ABIG
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 46.8 / 100 (HOLD) Higher Composite ABIG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BOLD vs ABIG Buy Guide
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABIG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABIG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BOLD nor ABIG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.